Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2013 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $40.6K | $40.9K | — | $72.1K | $72.1K | $72.1K | $72.1K |
| Revenue growth | — | — | — | — | 0.9% | — | — | 0.0% | 0.0% | 0.0% |
| Gross profit | — | — | — | $13.2K | -$135K | $66.3K | $66.3K | $66.3K | $66.3K | $27.8K |
| Gross margin | — | — | — | 32.5% | -330.4% | — | 91.9% | 91.9% | 91.9% | 38.6% |
| Operating income | — | -$491K | -$594K | -$930K | -$2.20M | -$2.74M | -$3.63M | -$3.86M | -$4.71M | -$4.28M |
| Operating margin | — | — | — | -2293.4% | -5380.2% | — | -5031.3% | -5347.4% | -6526.4% | -5937.0% |
| Net income | — | $357K | -$969K | -$1.01M | -$3.04M | $3.90M | -$3.91M | -$3.70M | -$4.39M | -$4.23M |
| Net margin | — | — | — | -2497.7% | -7422.5% | — | -5420.9% | -5132.6% | -6092.6% | -5863.5% |
| EPS (diluted) | — | $0.01 | -$0.02 | -$0.04 | -$0.05 | $0.04 | — | -$1.20 | -$1.19 | -$0.50 |
| Fiscal year | FY2013 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$182K | -$285K | $273K | -$794K | -$1.16M | -$2.28M | -$3.50M | -$3.22M | -$3.83M | -$4.66M |
| Share buybacks | — | — | — | — | — | — | — | — | $1.00M | — |
| Fiscal year | FY2013 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.01M | $295K | $337K | $112K | $1.13M | $9.84M | $11.4M | $3.52M | $3.91M | $4.75M |
| Total assets | $2.21M | $1.64M | $855K | $494K | $1.43M | $10.5M | $11.6M | $7.75M | $7.41M | $7.61M |
| Total liabilities | $18.7K | — | — | $117K | $146K | $1.43M | $1.30M | $1.57M | $2.38M | $1.30M |
| Shareholders' equity | $1.79M | $1.20M | $407K | -$22.9K | $1.28M | $9.06M | $10.3M | $6.18M | $5.03M | $6.31M |
| Retained earnings | — | — | -$1.64M | -$2.66M | -$5.76M | -$3.26M | -$7.17M | -$10.9M | -$15.3M | -$19.5M |
| Shares (wtd avg diluted) | 32.4M | 52.1M | 49.1M | 23.6M | 66.0M | 1.92M | 2.28M | 3.08M | 3.68M | 8.38M |
Every figure is extracted from Silo Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.